A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista
Regulatory Post Marketing Surveillance of Prezista 400mg Tablet
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Dae-Gu, Korea, Republic of
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who are prescribed with darunavir for treatment of Acquired Immune Deficiency Syndrome (AIDS)
Exclusion Criteria:
- Known hypersensitivity to Prezista
- Prezista coadministered with medicinal products that are highly dependent on CYP3A for clearance
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Darunavir
Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
|
This is an observational study.
Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks.
For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily.
For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with adverse events
Time Frame: Up to 30 days from end of treatment
|
Up to 30 days from end of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients with viral load
Time Frame: Screening, Week 12, Week 24
|
Screening, Week 12, Week 24
|
|
Number of patients with CD4 T-cell count
Time Frame: Screening, Week 12, Week 24
|
Screening, Week 12, Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Darunavir
Other Study ID Numbers
Other Study ID Numbers
- CR100805
- TMC114HIV4074 (Other Identifier: Janssen Korea, Ltd., Korea)
- Prezista PMS (Other Identifier: Janssen Korea, Ltd., Korea)
- DRV-C-11-KR-001-V06 (Other Identifier: Janssen Korea, Ltd., Korea)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.